AstraZeneca Agrees to Pay $51M in Pay-for-Delay Lawsuit

AstraZeneca PLC has agreed to pay $51 million to settle claims it entered into an unlawful deal to limit competition for antipsychotic drug Seroquel XR.

Direct purchaser plaintiffs on Thursday requested preliminary approval of the deal in the US District Court for the District of Delaware, after nearly six years of litigation.

“The proposed cash Settlements are in the best interests of the Class, since, if finally approved, the Settlements assure that Class members will receive substantial cash payments while avoiding the inherent risks of trial and potential appeal,” the plaintiffs said.

Read more at Bloomberg Law